Rucaparib
- Generic Name
- Rucaparib
- Brand Names
- Rubraca
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18FN3O
- CAS Number
- 283173-50-2
- Unique Ingredient Identifier
- 8237F3U7EH
- Background
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that la...
- Indication
Rucaparib is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
...
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer
- Associated Therapies
- Maintenance therapy
Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 13
- Registration Number
- NCT04826198
- Locations
- 🇫🇷
CHU Jean Minjoz, Besançon, Besancon, France
🇫🇷Hospices civils de Lyon(CHU Lyon Sud), Pierre-Bénite, Lyon, France
🇫🇷Institut de Cancérologie de l'Ouest - St Herblain, Saint-Herblain, Nantes, France
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 34
- Registration Number
- NCT04676334
- Locations
- 🇮🇱
Carmel Medical Center, Haifa, Israel
🇮🇹Istituto per la Ricerca e la Cura del Cancro Istituto di Candiolo, Candiolo, Torino, Italy
🇨🇦Institut De Recherche De L'Hospital D'Ottawa, Ottawa, Ontario, Canada
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04624178
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack (Limited protocol activities), Commack, New York, United States
🇺🇸Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
- Conditions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2022-09-23
- Target Recruit Count
- 52
- Registration Number
- NCT04539327
- Locations
- 🇪🇸
Hospital Torrecárdenas, Almería, Andalucía, Spain
🇪🇸Hospital Universitari i Politecnic La Fe, Valencia, Comunitat Valenciana, Spain
🇪🇸Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 130
- Registration Number
- NCT04276376
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Brown University
- Target Recruit Count
- 13
- Registration Number
- NCT04253262
- Locations
- 🇺🇸
Helen Diller Family Comprehensive Cancer Center University of California San Francisco, San Francisco, California, United States
🇺🇸Lifespan Cancer Institute, Providence, Rhode Island, United States
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 42
- Registration Number
- NCT04227522
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
🇩🇪Städtisches Klinikum Dessau, Dessau, Germany
🇩🇪Städtisches Krankenhaus Kiel, Kiel, Germany
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT04209595
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
- Conditions
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 8
- Registration Number
- NCT04179396
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Urology Associates, P.C., Nashville, Tennessee, United States
🇺🇸Piedmont Cancer Institute, P.C., Atlanta, Georgia, United States
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 83
- Registration Number
- NCT04171700
- Locations
- 🇺🇸
University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸New York Cancer and Blood Specialists, Port Jefferson Station, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.